08 May 2020 --- Nutrition companies have been forced to rethink their financial priorities as the COVID-19 pandemic continues to disrupt supply chains and tighten purse strings. Often it’s R&D that suffers when companies scale back during difficult times. However, lessons from the past show that R&D budgets must be prioritized in order to maintain momentum to industry innovation. NutritionInsight speaks with Valio, Monteloeder and American River Nutrition to get to the bottom of how the “new normal” is set to affect capital investment in R&D.
